tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Ascletis Pharma’s ASC47 Shows Promising Results in Obesity Treatment
Company AnnouncementsAscletis Pharma’s ASC47 Shows Promising Results in Obesity Treatment
8d ago
1672
Ascletis Pharma Reports Successful Phase III Trial Results for Acne Treatment
PremiumCompany Announcements
Ascletis Pharma Reports Successful Phase III Trial Results for Acne Treatment
12d ago
1672
Ascletis Pharma Reports Promising Phase Ib Results for Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma Reports Promising Phase Ib Results for Obesity Treatment
13d ago
1672
Ascletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical Trials
PremiumCompany Announcements
Ascletis Pharma’s Controlling Shareholders Commit to Share Lock-Up Amid Clinical Trials
18d ago
1672
Ascletis Pharma’s ASC30 Shows Promise in Obesity Management
PremiumCompany Announcements
Ascletis Pharma’s ASC30 Shows Promise in Obesity Management
21d ago
1672
Ascletis Pharma to Present Promising ASC30 Study Results at EASD Meeting
PremiumCompany AnnouncementsAscletis Pharma to Present Promising ASC30 Study Results at EASD Meeting
28d ago
1672
Ascletis Pharma Reports Promising Phase Ib Results for ASC30 in Obesity Treatment
Premium
Company Announcements
Ascletis Pharma Reports Promising Phase Ib Results for ASC30 in Obesity Treatment
1M ago
1672
Ascletis Pharma Completes Share Placing and Subscription to Boost R&D
Premium
Company Announcements
Ascletis Pharma Completes Share Placing and Subscription to Boost R&D
1M ago
1672
Ascletis Pharma Announces Share Placing and Subscription to Fund R&D
PremiumCompany Announcements
Ascletis Pharma Announces Share Placing and Subscription to Fund R&D
1M ago
1672
Ascletis Pharma’s Obesity Drug Candidates Show Promising Preclinical Results
PremiumCompany Announcements
Ascletis Pharma’s Obesity Drug Candidates Show Promising Preclinical Results
1M ago
1672
Ascletis Pharma Reports Reduced Losses and R&D Progress in Interim Results
PremiumCompany Announcements
Ascletis Pharma Reports Reduced Losses and R&D Progress in Interim Results
2M ago
1672
Ascletis Pharma’s ASC47 Shows Superior Efficacy in Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma’s ASC47 Shows Superior Efficacy in Obesity Treatment
2M ago
1672
Ascletis Completes Enrollment for Phase IIa Study of Obesity Drug ASC30
PremiumCompany AnnouncementsAscletis Completes Enrollment for Phase IIa Study of Obesity Drug ASC30
2M ago
1672
Ascletis Pharma Begins Phase IIa Study of ASC30 for Obesity Treatment
Premium
Company Announcements
Ascletis Pharma Begins Phase IIa Study of ASC30 for Obesity Treatment
2M ago
1672
Ascletis Pharma to Review Interim Results and Dividend Proposal
Premium
Company Announcements
Ascletis Pharma to Review Interim Results and Dividend Proposal
2M ago
1672
Ascletis Completes Dosing in U.S. Obesity Treatment Study
PremiumCompany Announcements
Ascletis Completes Dosing in U.S. Obesity Treatment Study
3M ago
1672
Ascletis Pharma Advances ASC30 in U.S. Phase IIa Obesity Study
PremiumCompany Announcements
Ascletis Pharma Advances ASC30 in U.S. Phase IIa Obesity Study
3M ago
1672
Ascletis Pharma Faces Patent Challenge from CSPC Subsidiary
PremiumCompany Announcements
Ascletis Pharma Faces Patent Challenge from CSPC Subsidiary
3M ago
1672
Ascletis Pharma Enhances Governance with New Nomination Committee Terms
PremiumCompany Announcements
Ascletis Pharma Enhances Governance with New Nomination Committee Terms
3M ago
1672
Ascletis Pharma Begins U.S. Phase I Trial for Psoriasis Drug ASC50
PremiumCompany AnnouncementsAscletis Pharma Begins U.S. Phase I Trial for Psoriasis Drug ASC50
3M ago
1672
Ascletis Pharma to Present Promising Obesity Treatments at ADA Scientific Sessions
Premium
Company Announcements
Ascletis Pharma to Present Promising Obesity Treatments at ADA Scientific Sessions
4M ago
1672
Ascletis Pharma’s Denifanstat Achieves Breakthrough in Acne Treatment
Premium
Company Announcements
Ascletis Pharma’s Denifanstat Achieves Breakthrough in Acne Treatment
4M ago
1672

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >